Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
25 February, 2018 13:30 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
MCX enhances maximum compensation limit to Rs 2.5 mn - 23-Feb-2018 10:31
Reliance Infra wins EPC contract worth Rs 36.47 bn - 23-Feb-2018 10:04
Larsen & Toubro bags orders worth Rs 12.66 bn - 23-Feb-2018 09:33
Vascon Engineers inks deal with Lina Ashar Foundation - 22-Feb-2018 13:15
Tata Comm partners with Taiwan's Chunghwa Telecom - 22-Feb-2018 10:57
Godrej Properties adds new residential project in Gurgaon - 22-Feb-2018 10:22
Indian Hume Pipe Co secures work order worth Rs 1.35 bn - 22-Feb-2018 10:15
Glenmark Pharma enters into collaboration with SDC Pharma - 22-Feb-2018 09:39
Lupin launches generic Namenda XR capsules in US - 21-Feb-2018 16:00
Lupin gets USFDA nod for generic Tamiflu for oral suspension - 21-Feb-2018 14:27
SSWL wins exports order from German OEM-BMW - 21-Feb-2018 12:15
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer